IceCure Medical (NASDAQ:ICCM – Get Free Report) is expected to announce its Q3 2026 results before the market opens on Wednesday, November 18th. Analysts expect IceCure Medical to post earnings of ($0.83) per share and revenue of $0.88 million for the quarter. Individuals can find conference call details on the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Wednesday, November 18, 2026 at 10:00 AM ET.
IceCure Medical Trading Up 4.1%
Shares of NASDAQ:ICCM opened at $0.76 on Tuesday. The firm’s fifty day moving average is $1.32 and its 200-day moving average is $7.00. IceCure Medical has a 52 week low of $0.65 and a 52 week high of $22.50.
Analysts Set New Price Targets
A number of analysts recently weighed in on ICCM shares. Zacks Research upgraded IceCure Medical from a “strong sell” rating to a “hold” rating in a report on Monday, October 12th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of IceCure Medical in a report on Thursday, October 15th. Finally, Wall Street Zen lowered IceCure Medical from a “hold” rating to a “sell” rating in a research report on Saturday, September 19th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, IceCure Medical has a consensus rating of “Hold” and an average price target of $30.00.
About IceCure Medical
IceCure Medical Ltd. is an Israel-based medical technology company that develops and commercializes minimally invasive cryoablation systems. Its technology uses liquid nitrogen to freeze and destroy targeted tissue, offering a percutaneous approach to treating tumors. The company’s ProSense system is designed for image-guided cryoablation and is used in procedures involving breast, kidney, lung, bone and other tumors. IceCure also offers the IceSense3 system for treating benign breast fibroadenomas.
Read More
- Five stocks we like better than IceCure Medical
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for IceCure Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IceCure Medical and related companies with MarketBeat.com's FREE daily email newsletter.
